Beneficial autoimmunity at body surfaces - immune surveillance and rapid type 2 immunity regulate tissue homeostasis and cancer

Frontiers in Immunology

Volumn 5, Issue JUL, 2014, Pages

  Dalessandri, Tim ^a   Strid, Jessica ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Carcinogenesis; Epithelial cells; Ige; Immune surveillance; Intraepithelial lymphocytes; Sterile stress; Tissue homeostasis; Type 2 immunity

Indexed keywords

EID: 84905665420     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00347     Document Type: Review

References (191)

1. Swamy M, Jamora C, Havran W, Hayday A. Epithelial decision makers: in search of the "epimmunome." Nat Immunol (2010) 11(8):656-65. doi: 10.1038/ni.1905
2. Nestle FO, Di Meglio P, Qin J-Z, Nickoloff BJ. Skin immune sentinels in health and disease. Nat Rev Immunol (2009) 9(10):679-91. doi:10.1038/nri2622
3. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature (2009) 461(7267):1071-8. doi:10.1038/nature08467
4. Wood LC, Elias PM, Calhoun C, Tsai JC, Grunfeld C, Feingold KR. Barrier disruption stimulates interleukin-1 alpha expression and release from a pre-formed pool in murine epidermis. J Invest Dermatol (1996) 106(3):397-403. doi:10.1111/1523-1747.ep12343392
5. Jerde TJ, Bushman W. IL-1 induces IGF-dependent epithelial proliferation in prostate development and reactive hyperplasia. Sci Signal (2009) 2(86):ra49. doi:10.1126/scisignal.2000338
6. Culig Z, Puhr M. Interleukin-6: a multifunctional targetable cytokine in human prostate cancer. Mol Cell Endocrinol (2012) 360(1-2):52-8. doi:10.1016/j.mce.2011.05.033
7. Fort MM, Cheung J, Yen D, Li J, Zurawski SM, Lo S, et al. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity (2001) 15(6):985-95. doi:10.1016/S1074-7613(01)00243-6
8. Lee J, Ho WH, Maruoka M, Corpuz RT, Baldwin DT, Foster JS, et al. IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1. J Biol Chem (2001) 276(2):1660-4. doi:10.1074/jbc.M008289200
9. Owyang AM, Zaph C, Wilson EH, Guild KJ, McClanahan T, Miller HRP, et al. Interleukin 25 regulates type 2 cytokine-dependent immunity and limits chronic inflammation in the gastrointestinal tract. J Exp Med (2006) 203(4):843-9. doi:10.1084/jem.20051496
10. Zaph C, Du Y, Saenz SA, Nair MG, Perrigoue JG, Taylor BC, et al. Commensal-dependent expression of IL-25 regulates the IL-23-IL-17 axis in the intestine. J Exp Med (2008) 205(10):2191-8. doi:10.1084/jem.20080720
11. Zaiss MM, Maslowski KM, Mosconi I, Guenat N, Marsland BJ, Harris NL. IL-1β suppresses innate IL-25 and IL-33 production and maintains helminth chronicity. PLoS Pathog (2013) 9(8):e1003531. doi:10.1371/journal.ppat.1003531
12. Heneghan AF, Pierre JF, Gosain A, Kudsk KA. IL-25 improves luminal innate immunity and barrier function during parenteral nutrition. Ann Surg (2014) 259(2):394-400. doi:10.1097/SLA.0b013e318284f510
13. Angkasekwinai P, Park H, Wang Y-H, Wang Y-H, Chang SH, Corry DB, et al. Interleukin 25 promotes the initiation of proallergic type 2 responses. J Exp Med (2007) 204(7):1509-17. doi:10.1084/jem.20061675
14. Wang Y-H, Angkasekwinai P, Lu N, Voo KS, Arima K, Hanabuchi S, et al. IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-activated Th2 memory cells. J Exp Med (2007) 204(8):1837-47. doi:10.1084/jem.20070406
15. Gregory LG, Jones CP, Walker SA, Sawant D, Gowers KHC, Campbell GA, et al. IL-25 drives remodelling in allergic airways disease induced by house dust mite. Thorax (2013) 68(1):82-90. doi:10.1136/thoraxjnl-2012-202003
16. Hams E, Armstrong ME, Barlow JL, Saunders SP, Schwartz C, Cooke G, et al. IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis. Proc Natl Acad Sci U S A (2014) 111(1):367-72. doi:10.1073/pnas.1315854111
17. Deleuran M, Hvid M, Kemp K, Christensen GB, Deleuran B, Vestergaard C. IL-25 induces both inflammation and skin barrier dysfunction in atopic dermatitis. Chem Immunol Allergy (2012) 96:45-9. doi:10.1159/000331871
18. Salimi M, Barlow JL, Saunders SP, Xue L, Gutowska-Owsiak D, Wang X, et al. A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J Exp Med (2013) 210(13):2939-50. doi:10.1084/jem.20130351
19. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity (2005) 23(5):479-90. doi:10.1016/j.immuni.2005.09.015
20. Komai-Koma M, Brombacher F, Pushparaj PN, Arendse B, McSharry C, Alexander J, et al. Interleukin-33 amplifies IgE synthesis and triggers mast cell degranulation via interleukin-4 in naïve mice. Allergy (2012) 67(9):1118-26. doi:10.1111/j.1398-9995.2012.02859.x
21. Humphreys NE, Xu D, Hepworth MR, Liew FY, Grencis RK. IL-33, a potent inducer of adaptive immunity to intestinal nematodes. J Immunol (2008) 180(4):2443-9. doi:10.4049/jimmunol.180.4.2443
22. Pastorelli L, Garg RR, Hoang SB, Spina L, Mattioli B, Scarpa M, et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci U S A (2010) 107(17):8017-22. doi:10.1073/pnas.0912678107
23. Fux M, Pecaric-Petkovic T, Odermatt A, Hausmann OV, Lorentz A, Bischoff SC, et al. IL-33 is a mediator rather than a trigger of the acute allergic response in humans. Allergy (2014) 69(2):216-22. doi:10.1111/all.12309
24. Imai Y, Yasuda K, Sakaguchi Y, Haneda T, Mizutani H, Yoshimoto T, et al. Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice. Proc Natl Acad Sci U S A (2013) 110(34):13921-6. doi:10.1073/pnas.1307321110
25. Hueber AJ, Alves-Filho JC, Asquith DL, Michels C, Millar NL, Reilly JH, et al. IL-33 induces skin inflammation with mast cell and neutrophil activation. Eur J Immunol (2011) 41(8):2229-37. doi:10.1002/eji.201041360
26. Yanaba K, Yoshizaki A, Asano Y, Kadono T, Sato S. Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Clin Rheumatol (2011) 30(6):825-30. doi:10.1007/s10067-011-1686-5
27. Yin H, Li X, Hu S, Liu T, Yuan B, Gu H, et al. IL-33 accelerates cutaneous wound healing involved in upregulation of alternatively activated macrophages. Mol Immunol (2013) 56(4):347-53. doi:10.1016/j.molimm.2013.05.225
28. Allakhverdi Z, Comeau MR, Jessup HK, Yoon B-RP, Brewer A, Chartier S, et al. Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J Exp Med (2007) 204(2):253-8. doi:10.1084/jem.20062211
29. Saenz SA, Taylor BC, Artis D. Welcome to the neighborhood: epithelial cell-derived cytokines license innate and adaptive immune responses at mucosal sites. Immunol Rev (2008) 226:172-90. doi:10.1111/j.1600-065X.2008.00713.x
30. Zaph C, Troy AE, Taylor BC, Berman-Booty LD, Guild KJ, Du Y, et al. Epithelial-cell-intrinsic IKK-beta expression regulates intestinal immune homeostasis. Nature (2007) 446(7135):552-6. doi:10.1038/nature05590
31. Ziegler SF, Artis D. Sensing the outside world: TSLP regulates barrier immunity. Nat Immunol (2010) 11(4):289-93. doi:10.1038/ni.1852
32. Al-Shami A, Spolski R, Kelly J, Keane-Myers A, Leonard WJ. A role for TSLP in the development of inflammation in an asthma model. J Exp Med (2005) 202(6):829-39. doi:10.1084/jem.20050199
33. Indra AK. Epidermal TSLP: a trigger factor for pathogenesis of atopic dermatitis. Expert Rev Proteomics (2013) 10(4):309-11. doi:10.1586/14789450.2013.814881
34. Yoo J, Omori M, Gyarmati D, Zhou B, Aye T, Brewer A, et al. Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin. J Exp Med (2005) 202(4):541-9. doi:10.1084/jem.20041503
35. Demehri S, Turkoz A, Manivasagam S, Yockey LJ, Turkoz M, Kopan R. Elevated epidermal thymic stromal lymphopoietin levels establish an antitumor environment in the skin. Cancer Cell (2012) 22(4):494-505. doi:10.1016/j.ccr.2012.08.017
36. Di Piazza M, Nowell CS, Koch U, Durham A-D, Radtke F. Loss of cutaneous TSLP-dependent immune responses skews the balance of inflammation from tumor protective to tumor promoting. Cancer Cell (2012) 22(4):479-93. doi:10.1016/j.ccr.2012.08.016
37. Jiang J, Hui C-C. Hedgehog signaling in development and cancer. Dev Cell (2008) 15(6):801-12. doi:10.1016/j.devcel.2008.11.010
38. Furmanski AL, Saldana JI, Ono M, Sahni H, Paschalidis N, D'Acquisto F, et al. Tissue-derived hedgehog proteins modulate Th differentiation and disease. J Immunol (2013) 190(6):2641-9. doi:10.4049/jimmunol.1202541
39. Kim J, Myers AC, Chen L, Pardoll DM, Truong-Tran Q-A, Lane AP, et al. Constitutive and inducible expression of b7 family of ligands by human airway epithelial cells. Am J Respir Cell Mol Biol (2005) 33(3):280-9. doi:10.1165/rcmb.2004-0129OC
40. Bas A, Swamy M, Abeler-Dörner L, Williams G, Pang DJ, Barbee SD, et al. Butyrophilin-like 1 encodes an enterocyte protein that selectively regulates functional interactions with T lymphocytes. Proc Natl Acad Sci U S A (2011) 108(11):4376-81. doi:10.1073/pnas.1010647108
41. Boyden LM, Lewis JM, Barbee SD, Bas A, Girardi M, Hayday AC, et al. Skint1, the prototype of a newly identified immunoglobulin superfamily gene cluster, positively selects epidermal γδ T cells. Nat Genet (2008) 40(5):656-62. doi:10.1038/ng.108
42. Turchinovich G, Hayday AC. Skint-1 identifies a common molecular mechanism for the development of interferon-γ-secreting versus interleukin-17-secreting γδ T cells. Immunity (2011) 35(1):59-68. doi:10.1016/j.immuni.2011.04.018
43. Rölle A, Mousavi-Jazi M, Eriksson M, Odeberg J, Söderberg-Nauclér C, Cosman D, et al. Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein. J Immunol (2003) 171(2):902-8. doi:10.4049/jimmunol.171.2.902
44. Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol (2013) 31(1):413-41. doi:10.1146/annurev-immunol-032712-095951
45. Jung H, Hsiung B, Pestal K, Procyk E, Raulet DH. RAE-1 ligands for the NKG2D receptor are regulated by E2F transcription factors, which control cell cycle entry. J Exp Med (2012) 209(13):2409-22. doi:10.1084/jem.20120565
46. Vantourout P, Hayday A. Six-of-the-best: unique contributions of γδ T cells to immunology. Nat Rev Immunol (2013) 13(2):88-100. doi:10.1038/nri3384
47. Cheroutre H, Lambolez F, Mucida D. The light and dark sides of intestinal intraepithelial lymphocytes. Nat Rev Immunol (2011) 11(7):445-56. doi:10.1038/nri3007
48. Gebhardt T, Wakim LM, Eidsmo L, Reading PC, Heath WR, Carbone FR. Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nat Immunol (2009) 10(5):524-30. doi:10.1038/ni.1718
49. Jiang X, Clark RA, Liu L, Wagers AJ, Fuhlbrigge RC, Kupper TS. Skin infection generates non-migratory memory CD8+ T(RM) cells providing global skin immunity. Nature (2012) 483(7388):227-31. doi:10.1038/nature10851
50. Eyerich S, Eyerich K, Pennino D, Carbone T, Nasorri F, Pallotta S, et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest (2009) 119(12):3573-85. doi:10.1172/JCI40202
51. Cella M, Fuchs A, Vermi W, Facchetti F, Otero K, Lennerz JKM, et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature (2008) 457(7230):722-5. doi:10.1038/nature07537
52. Björkström NK, Kekäläinen E, Mjösberg J. Tissue-specific effector functions of innate lymphoid cells. Immunology (2013) 139(4):416-27. doi:10.1111/imm.12098
53. Strid J, Sobolev O, Zafirova B, Polic B, Hayday A. The intraepithelial T cell response to NKG2D-ligands links lymphoid stress surveillance to atopy. Science (2011) 334(6060):1293-7. doi:10.1126/science.1211250
54. Harris N, Gause WC. To B or not to B: B cells and the Th2-type immune response to helminths. Trends Immunol (2011) 32(2):80-8. doi:10.1016/j.it.2010.11.005
55. Profet M. The function of allergy: immunological defense against toxins. Q Rev Biol (1991) 66(1):23-62. doi:10.1086/417049
56. Marichal T, Starkl P, Reber LL, Kalesnikoff J, Oettgen HC, Tsai M, et al. A beneficial role for immunoglobulin in host defense against honeybee venom. Immunity (2013) 39(5):963-75. doi:10.1016/j.immuni.2013.10.005
57. Palm NW, Rosenstein RK, Yu S, Schenten DD, Florsheim E, Medzhitov R. Bee venom phospholipase A2 induces a primary type 2 response that is dependent on the receptor ST2 and confers protective immunity. Immunity (2013) 39(5):976-85. doi:10.1016/j.immuni.2013.10.006
58. Palm NW, Rosenstein RK, Medzhitov R. Allergic host defences. Nature (2012) 484(7395):465-72. doi:10.1038/nature11047
59. Gutierrez DA, Rodewald H-R. A sting in the tale of Th2 immunity. Immunity (2013) 39(5):803-5. doi:10.1016/j.immuni.2013.10.015
60. Traidl-Hoffmann C, Jakob T, Behrendt H. Determinants of allergenicity. J Allergy Clin Immunol (2009) 123(3):558-66. doi:10.1016/j.jaci.2008.12.003
61. Kool M, Lambrecht BN. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med (2008) 205(4):869-82. doi:10.1084/jem.20071087
62. Fukuyama T, Tajima Y, Ueda H, Hayashi K, Shutoh Y, Saito TR, et al. Investigation of the chemical-induced selective type II (TH2) allergic response in mice: effect of the length of the sensitizing phase. J Immunotoxicol (2009) 6(2):75-83. doi:10.1080/15476910902891319
63. Dearman RJ, Basketter DA, Kimber I. Selective induction of type 2 cytokines following topical exposure of mice to platinum salts. Food Chem Toxicol (1998) 36(3):199-207. doi:10.1016/S0278-6915(97)00143-9
64. Jotwani R, Pulendran B, Agrawal S, Cutler CW. Human dendritic cells respond to Porphyromonas gingivalis LPS by promoting a Th2 effector response in vitro. Eur J Immunol (2003) 33(11):2980-6. doi:10.1002/eji.200324392
65. Salgame P, Yap GS, Gause WC. Effect of helminth-induced immunity on infections with microbial pathogens. Nat Immunol (2013) 14(11):1118-26. doi:10.1038/ni.2736
66. Bryson K, Besteiro S, McGachy HA, Coombs GH, Mottram JC, Alexander J. Overexpression of the natural inhibitor of cysteine peptidases in Leishmania mexicana leads to reduced virulence and a Th1 response. Infect Immun (2009) 77(7):2971-8. doi:10.1128/IAI.00558-08
67. Kuroda E, Ishii KJ, Uematsu S, Ohata K, Coban C, Akira S, et al. Silica crystals and aluminum salts regulate the production of prostaglandin in macrophages via NALP3 inflammasome-independent mechanisms. Immunity (2011) 34(4):514-26. doi:10.1016/j.immuni.2011.03.019
68. Mishra PK, Wu W, Rozo C, Hallab NJ, Benevenia J, Gause WC. Micrometer-sized titanium particles can induce potent Th2-type responses through TLR4-independent pathways. J Immunol (2011) 187(12):6491-8. doi:10.4049/jimmunol.1101392
69. Kool M, Willart MAM, van Nimwegen M, Bergen I, Pouliot P, Virchow JC, et al. An unexpected role for uric acid as an inducer of T helper 2 cell immunity to inhaled antigens and inflammatory mediator of allergic asthma. Immunity (2011) 34(4):527-40. doi:10.1016/j.immuni.2011.03.015
70. Marichal T, Ohata K, Bedoret D, Mesnil C, Sabatel C, Kobiyama K, et al. DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med (2011) 17(8):996-1002. doi:10.1038/nm.2403
71. Kouzaki H, Iijima K, Kobayashi T, O'Grady SM, Kita H. The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses. J Immunol (2011) 186(7):4375-87. doi:10.4049/jimmunol.1003020
72. Tang H, Cao W, Kasturi SP, Ravindran R, Nakaya HI, Kundu K, et al. The T helper type 2 response to cysteine proteases requires dendritic cell-basophil cooperation via ROS-mediated signaling. Nat Immunol (2010) 11(7):608-17. doi:10.1038/ni.1883
73. Moghaddam AE, Gartlan KH, Kong L, Sattentau QJ. Reactive carbonyls are a major Th2-inducing damage-associated molecular pattern generated by oxidative stress. J Immunol (2011) 187(4):1626-33. doi:10.4049/jimmunol.1003906
74. Chavanas S, Bodemer C, Rochat A, Hamel-Teillac D, Ali M, Irvine AD, et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet (2000) 25(2):141-2. doi:10.1038/75977
75. Walley AJ, Chavanas S, Moffatt MF, Esnouf RM, Ubhi B, Lawrence R, et al. Gene polymorphism in Netherton and common atopic disease. Nat Genet (2001) 29(2):175-8. doi:10.1038/ng728
76. Briot A, Deraison C, Lacroix M, Bonnart C, Robin A, Besson C, et al. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. J Exp Med (2009) 206(5):1135-47. doi:10.1084/jem.20082242
77. Fritz JH, Le Bourhis L, Sellge G, Magalhaes JG, Fsihi H, Kufer TA, et al. Nod1-mediated innate immune recognition of peptidoglycan contributes to the onset of adaptive immunity. Immunity (2007) 26(4):445-59. doi:10.1016/j.immuni.2007.03.009
78. Magalhaes JG, Fritz JH, Le Bourhis L, Sellge G, Travassos LH, Selvanantham T, et al. Nod2-dependent Th2 polarization of antigen-specific immunity. J Immunol (2008) 181(11):7925-35. doi:10.4049/jimmunol.181.11.7925
79. Magalhaes JG, Rubino SJ, Travassos LH, Le Bourhis L, Duan W, Sellge G, et al. Nucleotide oligomerization domain-containing proteins instruct T cell helper type 2 immunity through stromal activation. Proc Natl Acad Sci U S A (2011) 108(36):14896-901. doi:10.1073/pnas.1015063108
80. Eisenbarth SC, Piggott DA, Huleatt JW, Visintin I, Herrick CA, Bottomly K. Lipopolysaccharide-enhanced, Toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen. J Exp Med (2002) 196(12):1645-51. doi:10.1084/jem.20021340
81. Tan AM, Chen HC, Pochard P, Eisenbarth SC, Herrick CA, Bottomly HK. TLR4 signaling in stromal cells is critical for the initiation of allergic Th2 responses to inhaled antigen. J Immunol (2010) 184(7):3535-44. doi:10.4049/jimmunol.0900340
82. Agrawal S, Agrawal A, Doughty B, Gerwitz A, Blenis J, Van Dyke T, et al. Cutting edge: different toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. J Immunol (2003) 171(10):4984-9. doi:10.4049/jimmunol.171.10.4984
83. Hammad H, Chieppa M, Perros F, Willart MA, Germain RN, Lambrecht BN. House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. Nat Med (2009) 15(4):410-6. doi:10.1038/nm.1946
84. Schmidt M, Raghavan B, Müller V, Vogl T, Fejer G, Tchaptchet S, et al. Crucial role for human Toll-like receptor 4 in the development of contact allergy to nickel. Nat Immunol (2010) 11(9):814-9. doi:10.1038/ni.1919
85. Wen L, Roberts SJ, Viney JL, Wong FS, Mallick C, Findly RC, et al. Immunoglobulin synthesis and generalized autoimmunity in mice congenitally deficient in alpha beta(+) T cells. Nature (1994) 369(6482):654-8. doi:10.1038/369654a0
86. Wen L, Pao W, Wong FS, Peng Q, Craft J, Zheng B, et al. Germinal center formation, immunoglobulin class switching, and autoantibody production driven by "non alpha/beta" T cells. J Exp Med (1996) 183(5):2271-82. doi:10.1084/jem.183.5.2271
87. Aguado E, Richelme S, Nuñez-Cruz S, Miazek A, Mura A-M, Richelme M, et al. Induction of T helper type 2 immunity by a point mutation in the LAT adaptor. Science (2002) 296(5575):2036-40. doi:10.1126/science.1069057
88. Qi Q, Xia M, Hu J, Hicks E, Iyer A, Xiong N, et al. Enhanced development of CD4+ gammadelta T cells in the absence of Itk results in elevated IgE production. Blood (2009) 114(3):564-71. doi:10.1182/blood-2008-12-196345
89. Felices M, Yin CC, Kosaka Y, Kang J, Berg LJ. Tec kinase Itk in gamma delta T cells is pivotal for controlling IgE production in vivo. Proc Natl Acad Sci U S A (2009) 106(20):8308-13. doi:10.1073/pnas.0808459106
90. McCoy KD, Harris NL, Diener P, Hatak S, Odermatt B, Hangartner L, et al. Natural IgE production in the absence of MHC class II cognate help. Immunity (2006) 24(3):329-39. doi:10.1016/j.immuni.2006.01.013
91. Ehrlich P. Über den jetzigen Stand der Karzinomforschung. Ned Tijdschr Geneeskd (1909) 5:273-90.
92. Burnet M. Cancer; a biological approach. I. The processes of control. Br Med J (1957) 1(5022):779-86. doi:10.1136/bmj.1.5022.779
93. Burnet M. Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications. Br Med J (1957) 1(5023):841-7. doi:10.1136/bmj.1.5023.841
94. Thomas L. On immunosurveillance in human cancer. Yale J Biol Med (1982) 55(3-4):329-33.
95. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol (2004) 22(1):329-60. doi:10.1146/annurev.immunol.22.012703.104803
96. Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity (1994) 1(6):447-56. doi:10.1016/1074-7613(94)90087-6
97. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A (1998) 95(13):7556-61. doi:10.1073/pnas.95.13.7556
98. Shankaran V, Ikeda H, Bruce AT, White JM. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 410(6832):1107-11. doi:10.1038/35074122
99. Smyth MJ, Thia KY, Street SE, Cretney E, Trapani JA, Taniguchi M, et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med (2000) 191(4):661-8. doi:10.1084/jem.191.4.661
100. Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, et al. Regulation of cutaneous malignancy by gamma delta T cells. Science (2001) 294(5542):605-9. doi:10.1126/science.1063916
101. DePinho RA. The age of cancer. Nature (2000) 408(6809):248-54. doi:10.1038/35041694
102. Matzinger P. The danger model: a renewed sense of self. Science (2002) 296(5566):301-5. doi:10.1126/science.1071059
103. Chao MP, Majeti R, Weissman IL. Programmed cell removal: a new obstacle in the road to developing cancer. Nat Rev Cancer (2012) 12(1):58-67. doi:10.1038/nrc3171
104. Ma Y, Galluzzi L, Zitvogel L, Kroemer G. Autophagy and cellular immune responses. Immunity (2013) 39(2):211-27. doi:10.1016/j.immuni.2013.07.017
105. Zitvogel L, Kepp O, Galluzzi L, Kroemer G. Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol (2012) 13(4):343-51. doi:10.1038/ni.2224
106. Schonthaler HB, Guinea-Viniegra J, Wculek SK, Ruppen I, Ximénez-Embún P, Guío-Carrión A, et al. S100A8-S100A9 protein complex mediates psoriasis by regulating the expression of complement factor C3. Immunity (2013) 39(6):1171-81. doi:10.1016/j.immuni.2013.11.011
107. Ullrich E, Koch J, Cerwenka A, Steinle A. New prospects on the NKG2D/NKG2DL system for oncology. Oncoimmunology (2013) 2(10):e26097. doi:10.4161/onci.26097
108. Cerwenka A, Lanier LL. NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer. Tissue Antigens (2003) 61(5):335-43. doi:10.1034/j.1399-0039.2003.00070.x
109. Van Belle TL, von Herrath MG. The role of the activating receptor NKG2D in autoimmunity. Mol Immunol (2009) 47(1):8-11. doi:10.1016/j.molimm.2009.02.023
110. Suárez-Alvarez B, López-Vázquez A, Baltar JM, Ortega F, López-Larrea C. Potential role of NKG2D and its ligands in organ transplantation: new target for immunointervention. Am J Transplant (2009) 9(2):251-7. doi:10.1111/j.1600-6143.2008.02526.x
111. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature (2002) 419(6908):734-8. doi:10.1038/nature01112
112. Lodoen MB, Lanier LL. Viral modulation of NK cell immunity. Nat Rev Microbiol (2005) 3(1):59-69. doi:10.1038/nrmicro1066
113. Champsaur M, Lanier LL. Effect of NKG2D ligand expression on host immune responses. Immunol Rev (2010) 235(1):267-85. doi:10.1111/j.0105-2896.2010.00893.x
114. Strid J, Roberts SJ, Filler RB, Lewis JM, Kwong BY, Schpero W, et al. Acute upregulation of an NKG2D ligand promotes rapid reorganization of a local immune compartment with pleiotropic effects on carcinogenesis. Nat Immunol (2008) 9(2):146-54. doi:10.1038/ni1556
115. Strid J, Tigelaar RE, Hayday AC. Skin immune surveillance by T cells - a new order? Semin Immunol (2009) 21(3):110-20. doi:10.1016/j.smim.2009.03.002
116. Hayday AC. Gammadelta T cells and the lymphoid stress-surveillance response. Immunity (2009) 31(2):184-96. doi:10.1016/j.immuni.2009.08.006
117. Takai Y, Irie K, Shimizu K, Sakisaka T, Ikeda W. Nectins and nectin-like molecules: roles in cell adhesion, migration, and polarization. Cancer Sci (2003) 94(8):655-67. doi:10.1111/j.1349-7006.2003.tb01499.x
118. Giangreco A, Jensen KB, Takai Y, Miyoshi J, Watt FM. Necl2 regulates epidermal adhesion and wound repair. Development (2009) 136(20):3505-14. doi:10.1242/dev.038232
119. Chan CJ, Andrews DM, Smyth MJ. Receptors that interact with nectin and nectin-like proteins in the immunosurveillance and immunotherapy of cancer. Curr Opin Immunol (2012) 24(2):246-51. doi:10.1016/j.coi.2012.01.009
120. Soriani A, Zingoni A, Cerboni C, Iannitto ML, Ricciardi MR, Di Gialleonardo V, et al. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood (2009) 113(15):3503-11. doi:10.1182/blood-2008-08-173914
121. Shibuya A, Campbell D, Hannum C, Yssel H, Franz-Bacon K, McClanahan T, et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity (1996) 4(6):573-81. doi:10.1016/S1074-7613(00)70060-4
122. Ramsbottom KM, Hawkins ED, Shimoni R, McGrath M, Chan CJ, Russell SM, et al. Cutting edge: DNAX accessory molecule 1-deficient CD8+ T cells display immunological synapse defects that impair antitumor immunity. J Immunol (2014) 192(2):553-7. doi:10.4049/jimmunol.1302197
123. Takahashi Y, Iwai M, Kawai T, Arakawa A, Ito T, Sakurai-Yageta M, et al. Aberrant expression of tumor suppressors CADM1 and 4.1B in invasive lesions of primary breast cancer. Breast Cancer (2012) 19(3):242-52. doi:10.1007/s12282-011-0272-7
124. Witherden DA, Verdino P, Rieder SE, Garijo O, Mills RE, Teyton L, et al. The junctional adhesion molecule JAML is a costimulatory receptor for epithelial gamma delta T cell activation. Science (2010) 329(5996):1205-10. doi:10.1126/science.1192698
125. Verdino P, Witherden DA, Havran WL, Wilson IA. The molecular interaction of CAR and JAML recruits the central cell signal transducer PI3K. Science (2010) 329(5996):1210-4. doi:10.1126/science.1187996
126. Witherden DA, Watanabe M, Garijo O, Rieder SE, Sarkisyan G, Cronin SJF, et al. The CD100 receptor interacts with its plexin B2 ligand to regulate epidermal γδ T cell function. Immunity (2012) 37(2):314-25. doi:10.1016/j.immuni.2012.05.026
127. Meehan TF, Witherden DA, Kim C-H, Sendaydiego K, Ye I, Garijo O, et al. Protection against colitis by CD100-dependent modulation of intraepithelial γδ T lymphocyte function. Mucosal Immunol (2014) 7(1):134-42. doi:10.1038/mi.2013.32
128. Shi W, Kumanogoh A, Watanabe C, Uchida J, Wang X, Yasui T, et al. The class IV semaphorin CD100 plays nonredundant roles in the immune system: defective B and T cell activation in CD100-deficient mice. Immunity (2000) 13(5):633-42. doi:10.1016/S1074-7613(00)00063-7
129. Park O, Jeong W-I, Wang L, Wang H, Lian Z-X, Gershwin ME, et al. Diverse roles of invariant natural killer T cells in liver injury and fibrosis induced by carbon tetrachloride. Hepatology (2009) 49(5):1683-94. doi:10.1002/hep.22813
130. Sagiv A, Biran A, Yon M, Simon J, Lowe SW, Krizhanovsky V. Granule exocytosis mediates immune surveillance of senescent cells. Oncogene (2013) 32(15):1971-7. doi:10.1038/onc.2012.206
131. Devey L, Ferenbach D, Mohr E, Sangster K, Bellamy CO, Hughes J, et al. Tissue-resident macrophages protect the liver from ischemia reperfusion injury via a heme oxygenase-1-dependent mechanism. Mol Ther (2009) 17(1):65-72. doi:10.1038/mt.2008.237
132. Girardi M, Lewis J, Glusac E, Filler RB, Geng L, Hayday AC, et al. Resident skin-specific gamma delta T cells provide local, non-redundant regulation of cutaneous inflammation. J Exp Med (2002) 195(7):855-67. doi:10.1084/jem.20012000
133. Girardi M, Lewis JM, Filler RB, Hayday AC, Tigelaar RE. Environmentally responsive and reversible regulation of epidermal barrier function by γδ T cells. J Invest Dermatol (2006) 126(4):808-14. doi:10.1038/sj.jid.5700120
134. Sharp LL, Jameson JM, Cauvi G, Havran WL. Dendritic epidermal T cells regulate skin homeostasis through local production of insulin-like growth factor 1. Nat Immunol (2005) 6(1):73-9. doi:10.1038/ni1152
135. Jameson J, Havran WL. Skin gammadelta T-cell functions in homeostasis and wound healing. Immunol Rev (2007) 215:114-22. doi:10.1111/j.1600-065X.2006.00483.x
136. Jameson J, Ugarte K, Chen N, Yachi P, Fuchs E, Boismenu R, et al. A role for skin gamma delta T cells in wound repair. Science (2002) 296(5568):747-9. doi:10.1126/science.1069639
137. Chen Y, Chou K, Fuchs E, Havran WL, Boismenu R. Protection of the intestinal mucosa by intraepithelial gamma delta T cells. Proc Natl Acad Sci U S A (2002) 99(22):14338-43. doi:10.1073/pnas.212290499
138. Senovilla L, Galluzzi L, Zitvogel L, Kroemer G. Immunosurveillance as a regulator of tissue homeostasis. Trends Immunol (2013) 34(10):471-81. doi:10.1016/j.it.2013.06.005
139. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol (2011) 29(1):235-71. doi:10.1146/annurev-immunol-031210-101324
140. Dunham LJ. Cancer in man at site of prior benign lesion of skin or mucous membrane: a review. Cancer Res (1972) 32(7):1359-74.
141. Walter ND, Rice PL, Redente EF, Kauvar EF, Lemond L, Aly T, et al. Wound healing after trauma may predispose to lung cancer metastasis: review of potential mechanisms. Am J Respir Cell Mol Biol (2011) 44(5):591-6. doi:10.1165/rcmb.2010-0187RT
142. Ortiz-Urda S. Type VII collagen is required for ras-driven human epidermal tumorigenesis. Science (2005) 307(5716):1773-6. doi:10.1126/science.1106209
143. South AP, O'Toole EA. Understanding the pathogenesis of recessive dystrophic epidermolysis bullosa squamous cell carcinoma. Dermatol Clin (2010) 28(1):171-8. doi:10.1016/j.det.2009.10.023
144. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med (1986) 315(26):1650-9. doi:10.1056/NEJM198612253152606
145. Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science (2013) 339(6117):286-91. doi:10.1126/science.1232227
146. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet (2001) 357(9255):539-45. doi:10.1016/S0140-6736(00)04046-0
147. Farhadi N, Lambert L, Triulzi C, Openshaw PJ, Guerra N. Natural killer cell NKG2D and granzyme B are critical for allergic pulmonary inflammation. J Allergy Clin Immunol (2014) 133(3):827-35. doi:10.1016/j.jaci.2013.09.048
148. Oh M-H, Oh SY, Yu J, Myers AC, Leonard WJ, Liu YJ, et al. IL-13 induces skin fibrosis in atopic dermatitis by thymic stromal lymphopoietin. J Immunol (2011) 186(12):7232-42. doi:10.4049/jimmunol.1100504
149. Wilson SR, Thé L, Batia LM, Beattie K, Katibah GE, McClain SP, et al. The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch. Cell (2013) 155(2):285-95. doi:10.1016/j.cell.2013.08.057
150. Metz M, Piliponsky AM, Chen CC, Lammel V, Abrink M, Pejler G, et al. Mast cells can enhance resistance to snake and honeybee venoms. Science (2006) 313(5786):526-30. doi:10.1126/science.1128877
151. Schneider LA, Schlenner SM, Feyerabend TB, Wunderlin M, Rodewald H-R. Molecular mechanism of mast cell mediated innate defense against endothelin and snake venom sarafotoxin. J Exp Med (2007) 204(11):2629-39. doi:10.1084/jem.20071262
152. Matsuda H, Watanabe N, Kiso Y, Hirota S, Ushio H, Kannan Y, et al. Necessity of IgE antibodies and mast cells for manifestation of resistance against larval Haemaphysalis longicornis ticks in mice. J Immunol (1990) 144(1):259-62.
153. Pearce EJ, Cheever A, Leonard S, Covalesky M, Fernandez-Botran R, Kohler G, et al. Schistosoma mansoni in IL-4-deficient mice. Int Immunol (1996) 8(4):435-44. doi:10.1093/intimm/8.4.435
154. Gause WC, Wynn TA, Allen JE. Type 2 immunity and wound healing: evolutionary refinement of adaptive immunity by helminths. Nat Rev Immunol (2013) 13(8):607-14. doi:10.1038/nri3476
155. Monticelli LA, Sonnenberg GF, Abt MC, Alenghat T, Ziegler CGK, Doering TA, et al. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat Immunol (2011) 12(11):1045-54. doi:10.1031/ni.2131
156. Rosenberg HF, Dyer KD, Foster PS. Eosinophils: changing perspectives in health and disease. Nat Rev Immunol (2013) 13(1):9-22. doi:10.1038/nri3341
157. Okumura S, Sagara H, Fukuda T, Saito H, Okayama Y. FcεRI-mediated amphiregulin production by human mast cells increases mucin gene expression in epithelial cells. J Allergy Clin Immunol (2005) 115(2):272-9. doi:10.1016/j.jaci.2004.12.835
158. Arwert EN, Hoste E, Watt FM. Epithelial stem cells, wound healing and cancer. Nat Rev Cancer (2012) 12(3):170-80. doi:10.1038/nrc3217
159. Conticello C, Pedini F, Zeuner A, Patti M, Zerilli M, Stassi G, et al. IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins. J Immunol (2004) 172(9):5467-77. doi:10.4049/jimmunol.172.9.5467
160. Golumbek PT, Lazenby AJ, Levitsky HI, Jaffee LM, Karasuyama H, Baker M, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science (1991) 254(5032):713-6. doi:10.1126/science.1948050
161. Hock H, Dorsch M, Kunzendorf U, Qin Z, Diamantstein T, Blankenstein T. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma. Proc Natl Acad Sci U S A (1993) 90(7):2774-8. doi:10.1073/pnas.90.7.2774
162. Pericle F, Giovarelli M, Colombo MP, Ferrari G, Musiani P, Modesti A, et al. An efficient Th2-type memory follows CD8+ lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4. J Immunol (1994) 153(12):5659-73.
163. Rodolfo M, Zilocchi C, Accornero P, Cappetti B, Arioli I, Colombo MP. IL-4-transduced tumor cell vaccine induces immunoregulatory type 2 CD8 T lymphocytes that cure lung metastases upon adoptive transfer. J Immunol (1999) 163(4):1923-8.
164. Ellyard JI, Simson L, Parish CR. Th2-mediated anti-tumour immunity: friend or foe? Tissue Antigens (2007) 70(1):1-11. doi:10.1111/j.1399-0039.2007.00869.x
165. Chen S-F, Nieh S, Jao S-W, Wu M-Z, Liu C-L, Chang Y-C, et al. The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma. J Pathol (2013) 231(2):180-9. doi:10.1002/path.4226
166. Pedroza-Gonzalez A, Xu K, Wu T-C, Aspord C, Tindle S, Marches F, et al. Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. J Exp Med (2011) 208(3):479-90. doi:10.1084/jem.20102131
167. Hallett MA, Venmar KT, Fingleton B. Cytokine stimulation of epithelial cancer cells: the similar and divergent functions of IL-4 and IL-13. Cancer Res (2012) 72(24):6338-43. doi:10.1158/0008-5472.CAN-12-3544
168. Renard N, Duvert V, Banchereau J, Saeland S. Interleukin-13 inhibits the proliferation of normal and leukemic human B-cell precursors. Blood (1994) 84(7):2253-60.
169. Blais Y, Gingras S, Haagensen DE, Labrie F, Simard J. Interleukin-4 and interleukin-13 inhibit estrogen-induced breast cancer cell proliferation and stimulate GCDFP-15 expression in human breast cancer cells. Mol Cell Endocrinol (1996) 121(1):11-8. doi:10.1016/0303-7207(96)03843-9
170. Obiri NI, Husain SR, Debinski W, Puri RK. Interleukin 13 inhibits growth of human renal cell carcinoma cells independently of the p140 interleukin 4 receptor chain. Clin Cancer Res (1996) 2(10):1743-9.
171. Fujisawa T, Joshi BH, Puri RK. IL-13 regulates cancer invasion and metastasis through IL-13Rα2 via ERK/AP-1 pathway in mouse model of human ovarian cancer. Int J Cancer (2012) 131(2):344-56. doi:10.1002/ijc.26366
172. Simson L, Ellyard JI, Dent LA, Matthaei KI, Rothenberg ME, Foster PS, et al. Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J Immunol (2007) 178(7):4222-9. doi:10.4049/jimmunol.178.7.4222
173. Dalton DK, Noelle RJ. The roles of mast cells in anticancer immunity. Cancer Immunol Immunother (2012) 61(9):1511-20. doi:10.1007/s00262-012-1246-0
174. Vernersson M, Aveskogh M, Hellman L. Cloning of IgE from the echidna (Tachyglossus aculeatus) and a comparative analysis of epsilon chains from all three extant mammalian lineages. Dev Comp Immunol (2004) 28(1):61-75. doi:10.1016/S0145-305X(03)00084-3
175. Jensen-Jarolim E, Achatz G, Turner MC, Karagiannis S, Legrand F, Capron M, et al. AllergoOncology: the role of IgE-mediated allergy in cancer. Allergy (2008) 63(10):1255-66. doi:10.1111/j.1398-9995.2008.01768.x
176. Reali E, Greiner JW, Corti A, Gould HJ, Bottazzoli F, Paganelli G, et al. IgEs targeted on tumor cells: therapeutic activity and potential in the design of tumor vaccines. Cancer Res (2001) 61(14):5517-22.
177. Karagiannis P, Gilbert AE, Josephs DH, Ali N, Dodev T, Saul L, et al. IgG4 subclass antibodies impair antitumor immunity in melanoma. J Clin Invest (2013) 123(4):1457-74. doi:10.1172/JCI65579
178. Olver S, Groves P, Buttigieg K, Morris ES, Janas ML, Kelso A, et al. Tumor-derived interleukin-4 reduces tumor clearance and deviates the cytokine and granzyme profile of tumor-induced CD8+ T cells. Cancer Res (2006) 66(1):571-80. doi:10.1158/0008-5472.CAN-05-1362
179. Lebel-Binay S, Laguerre B, Quintin-Colonna F, Conjeaud H, Magazin M, Miloux B, et al. Experimental gene therapy of cancer using tumor cells engineered to secrete interleukin-13. Eur J Immunol (1995) 25(8):2340-8. doi:10.1002/eji.1830250833
180. Skinnider BF, Elia AJ, Gascoyne RD, Patterson B, Trumper L, Kapp U, et al. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood (2002) 99(2):618-26. doi:10.1182/blood.V99.2.618
181. Jovanovic I, Radosavljevic G, Mitrovic M, Juranic VL, McKenzie ANJ, Arsenijevic N, et al. ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma. Eur J Immunol (2011) 41(7):1902-12. doi:10.1002/eji.201141417
182. Jovanovic IP, Pejnovic NN, Radosavljevic GD, Pantic JM, Milovanovic MZ, Arsenijevic NN, et al. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int J Cancer (2013) 134(7):1669-82. doi:10.1002/ijc.28481
183. Villarreal D, Wise MC, Walters JN, Reuschel E, Choi MJ, Obeng-Adjei N, et al. Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. Cancer Res (2014) 74(6):1-12. doi:10.1158/0008-5472.CAN-13-2729
184. Nigro EA, Brini AT, Soprana E, Ambrosi A, Dombrowicz D, Siccardi AG, et al. Antitumor IgE adjuvanticity: key role of Fc RI. J Immunol (2009) 183(7):4530-6. doi:10.4049/jimmunol.0900842
185. McWhorter WP. Allergy and risk of cancer. A prospective study using NHANESI follow up data. Cancer (1988) 62(2):451-5. doi:10.1002/1097-0142(19880715)62:2<451::AID-CNCR2820620234>3.0.CO;2-D
186. Josephs DH, Spicer JF, Corrigan CJ, Gould HJ, Karagiannis SN. Epidemiological associations of allergy, IgE and cancer. Clin Exp Allergy (2013) 43(10):1110-23. doi:10.1111/cea.12178
187. Sherman PW, Holland E, Sherman JS. Allergies: their role in cancer prevention. Q Rev Biol (2008) 83(4):339-62. doi:10.1086/592850
188. Rittmeyer D, Lorentz A. Relationship between allergy and cancer: an overview. Int Arch Allergy Immunol (2012) 159(3):216-25. doi:10.1159/000338994
189. Engkilde K, Thyssen JP, Menné T, Johansen JD. Association between cancer and contact allergy: a linkage study. BMJ Open (2011) 1(1):e000084. doi:10.1136/bmjopen-2011-000084
190. Van Hemelrijck M, Garmo H, Binda E, Hayday A, Karagiannis SN, Hammar N, et al. Immunoglobulin E and cancer: a meta-analysis and a large Swedish cohort study. Cancer Causes Control (2010) 21(10):1657-67. doi:10.1007/s10552-010-9594-6
191. Lindelof B, Granath F, Tengvall-Linder M, Ekbom A. Allergy and cancer. Allergy (2005) 60(9):1116-20. doi:10.1111/j.1398-9995.2005.00808.x